Health care stocks advanced Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.4%.
The iShares Biotechnology ETF (IBB) rose 1.8%.
In corporate news, Pfizer (PFE) secured exclusive global rights, excluding China, to biopharmaceutical firm 3SBio's cancer treatment candidate in a licensing deal worth up to $6.05 billion. Pfizer shares gained 2.1%.
The US Food and Drug Administration plans to require new clinical trials prior to approval of COVID-19 boosters for healthy Americans under the age of 65, agency leaders said Tuesday in a post published on the New England Journal of Medicine. Moderna (MRNA) shares were rising past 8%.
NeurAxis' (NRXS) shares jumped more than 64% after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device to treat functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。